title: The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution.
abstract: OBJECTIVE
  To study vancomycin-resistant Enterococcus (VRE) prevalence, risk factors, and clustering among hospital inpatients.
  
  
  METHODS
  Rectal-swab prevalence culture survey conducted from February 5 to March 22, 1996.
  
  
  METHODS
  The Veterans' Affairs Medical Center, Atlanta, Georgia.
  
  
  METHODS
  Hospital (medical and surgical) inpatients.
  
  
  RESULTS
  The overall VRE prevalence was 29% (42/147 patients). The VRE prevalence was 52% (38/73 patients) among patients who had received at least one of six specific antimicrobials during the preceding 120 days, compared with only 5% (4/74) among those who had not received the antimicrobials (relative risk, 9.6; P<.001). The longer the period (up to 120 days) during which antimicrobial use was studied, the more closely VRE status was predicted. Among 67 hospital patients in 28 multibed rooms, clustering of VRE among current roommates was not found.
  
  
  CONCLUSIONS
  At this hospital with relatively high VRE prevalence, VRE colonization was related to antibiotic use but not to roommate VRE status. In hospitals with a similar VRE epidemiology, obtaining cultures from roommates of VRE-positive patients may not be as efficient a strategy for identifying VRE-colonized patients as obtaining screening cultures from patients who have received antimicrobials.
authors: Hospital Infections Program, Centers for Disease Control and Prevention, Veterans' Affairs Medical Center, Atlanta, GA 30333, USA.
authors: J I
authors: JI
authors: Tokars
authors: S
authors: S
authors: Satake
authors: D
authors: D
authors: Rimland
authors: L
authors: L
authors: Carson
authors: E R
authors: ER
authors: Miller
authors: E
authors: E
authors: Killum
authors: R L
authors: RL
authors: Sinkowitz-Cochran
authors: M J
authors: MJ
authors: Arduino
authors: F C
authors: FC
authors: Tenover
authors: B
authors: B
authors: Marston
authors: W R
authors: WR
authors: Jarvis
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000453:epidemiology* / Q000382:microbiology / Q000635:transmission; D003428:Cross Infection / Q000453:epidemiology* / Q000382:microbiology / Q000635:transmission; D018562:Disease Transmission, Infectious; D004352:Drug Resistance, Microbial; D016521:Electrophoresis, Gel, Pulsed-Field; D016983:Enterococcus / Q000187:drug effects / Q000302:isolation & purification*; D005260:Female; D005845:Georgia / Q000453:epidemiology; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology / Q000635:transmission; D006787:Hospitals, Veterans / Q000706:statistics & numerical data*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin